In a nutshell
This study aimed to evaluate the relationship between minimal residual disease response and outcomes in patients with relapsed/unresponsive B-cell precursor acute lymphoblastic leukemia who were treated with blinatumomab.
This study concluded that achieving minimal residual disease response leads to better outcomes for these patients.
Blinatumomab (Blincyto) is a drug used as a second-line treatment for relapsed or refractory (unresponsive) acute lymphoblastic leukemia (r/r ALL).
Minimal residual disease (MRD) is where cancer cell levels are lower than a specific level. MRD is the most important prognostic factor (indicates outcome for a patient) for ALL relapse during first-line chemotherapy treatment. MRD is the standard of care (SOC) in treatment monitoring and decision making. The prognostic value of MRD response after relapse is unknown.
Methods & findings
This study involved 90 patients with r/r B-cell precursor ALL. All patients previously had a complete remission (CR – no signs of cancer) or CR with partial hematologic recovery (CRh). Patients had been treated with blinatumomab.
71.1% of patients achieved complete MRD response (no detectable MRD). 12.2% of patients had MRD. Overall, 83.3% of patients experienced an MRD response within the first two treatment cycles.
Overall survival (OS) for patients who achieved CR/CRh and MRD response was 20.6 months compared to 12.5 months for patients who achieved CR/CRh without MRD response. Relapse-free survival (RFS) for patients who achieved CR/CRh and MRD response was 9.0 months compared to 2.3 months for patients who achieved CR/CRh without MRD response.
The bottom line
This study concluded that achieving MRD response leads to longer durations of OS and RFS in patients with r/r ALL who achieve CR or CRh after treatment with blinatumomab.
The fine print
This study had a small number of participants. Also, the study was funded by Amgen, the manufacturer of blinatumomab.
Published By :
Oct 22, 2019